rucaparib: Clinical Trials

23 trials of rucaparib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 5 terminated, 3 unknown, 1 active not recruiting. 23 Phase 1, 11 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 123Completed 14, Terminated 5, Unknown 3, Active not recruiting 1
Phase 211Terminated 5, Unknown 3, Completed 2, Active not recruiting 1

Follow rucaparib: new trials by email Literature Review of rucaparib trials Research Report on rucaparib

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination
Carboplatin, Paclitaxel, Bevacizumab - Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Phase 1 / Phase 2UnknownFondazione Policlinico Universitario Agostino Gemelli IRCCS2902021-03-172021-08-27
Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months
AsiDNA, Niraparib, Olaparib - Ovarian Cancer
Phase 1 / Phase 2TerminatedGustave Roussy, Cancer Campus, Grand Paris132020-10-052024-12-05
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
PLX038, Rucaparib, Ondansetron - Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)102020-04-082026-08-26
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Rucaparib, Copanlisib - Metastatic Castration-resistant Prostate Cancer
Phase 1 / Phase 2Active not recruitingBrown University132020-04-032025-05-04
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma
Rucaparib, Ramucirumab, Nivolumab - Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma
Phase 1 / Phase 2UnknownUniversity of Kansas Medical Center342020-01-092023-02-01
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
Rucaparib, Enzalutamide, Abiraterone - Metastatic Castration Resistant Prostate Cancer
Phase 1Completedpharmaand GmbH82019-12-052023-06-29
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
Rucaparib, Lucitanib, Sacituzumab govitecan - Ovarian Cancer, Triple-negative Breast Cancer
Phase 1 / Phase 2Terminatedpharmaand GmbH252019-06-282024-01-16
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Ipatasertib, Rucaparib - Breast Cancer, Prostate Cancer
Phase 1CompletedHoffmann-La Roche512019-06-122023-10-30
Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives
Rucaparib, Rosuvastatin, Oral Contraceptives - Neoplasms
Phase 1Completedpharmaand GmbH362019-04-252023-06-08
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Pembrolizumab, Pemetrexed, Carboplatin - Stage IV Non-small Cell Lung Cancer
Phase 1 / Phase 2TerminatedUniversity of Michigan Rogel Cancer Center252018-12-242026-02-12
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis - Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma
Phase 1 / Phase 2UnknownAcademic and Community Cancer Research United182018-11-022024-05-17
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
Rucaparib, Nivolumab - Prostate Cancer, Endometrial Cancer
Phase 1 / Phase 2TerminatedUniversity of Chicago122018-08-142021-03-09
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study - BRCA1 Gene Mutation, BRCA2 Gene Mutation
Phase 1CompletedOhio State University Comprehensive Cancer Center252018-07-122025-02-13
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Rucaparib, Radiotherapy - Breast Cancer
Phase 1CompletedMemorial Sloan Kettering Cancer Center312018-05-232025-12-08
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
Rucaparib camsylate - Neoplasms
Phase 1Completedpharmaand GmbH162018-02-272023-06-09
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
Rucaparib - Advanced Solid Tumor
Phase 1Completedpharmaand GmbH292018-02-062023-06-09
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
Rucaparib, Irinotecan - Solid Tumor, Unspecified, Adult
Phase 1CompletedPamela Munster222018-01-122021-03-04
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
Atezolizumab, Rucaparib - Gynecologic Neoplasms
Phase 1CompletedHoffmann-La Roche292017-04-272020-10-22
Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib
C-14 labeled Rucaparib, Rucaparib - Solid Tumor
Phase 1Completedpharmaand GmbH62016-11-012023-06-09
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
INCB057643, Gemcitabine, Paclitaxel - Solid Tumors
Phase 1 / Phase 2TerminatedIncyte Corporation1372016-05-182025-10-21

Showing 20 of 23. Sign in to see all of them.

Conditions studied

Ovarian Neoplasms (6)  ·  Breast Neoplasms (3)  ·  Fallopian Tube Neoplasms (3)  ·  Neoplasms (3)  ·  Prostatic Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Colorectal Neoplasms (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Adenocarcinoma Of Esophagus (1)  ·  Carcinoma, Transitional Cell (1)  ·  Endometrial Neoplasms (1)  ·  Gastrointestinal Neoplasms (1)  ·  Genital Neoplasms, Female (1)  ·  Glioblastoma (1)

Sponsors

pharmaand GmbH (9)  ·  Hoffmann-La Roche (2)  ·  Academic and Community Cancer Research United (1)  ·  Brown University (1)  ·  Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  Incyte Corporation (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  Ohio State University Comprehensive Cancer Center (1)  ·  Pamela Munster (1)  ·  University of Chicago (1)  ·  University of Kansas Medical Center (1)  ·  University of Michigan Rogel Cancer Center (1)

Countries

United States (14)  ·  United Kingdom (4)  ·  France (3)  ·  Poland (3)  ·  Spain (3)  ·  Australia (2)  ·  Hungary (2)  ·  Italy (2)  ·  Slovakia (2)  ·  Belgium (1)  ·  Canada (1)  ·  Israel (1)  ·  Japan (1)  ·  South Korea (1)

Top investigators

Angel Qin, MD (1)  ·  Anwaar Saeed, MD (1)  ·  Atif Khan, MD (1)  ·  Benedito Carneiro, MD, MS (1)  ·  Domenica Lorusso, Prof. (1)  ·  Floor Backes, MD (1)  ·  Fred Zheng, MD, PhD (1)  ·  James Gulley, M.D. (1)  ·  Pamela Munster, MD (1)  ·  Tanios S Bekaii-Saab (1)  ·  Walter Stadler, MD (1)

Results publications

PMID 35397664, PMID 10623700, PMID 10628376, PMID 10793106, PMID 11309294, PMID 11331762, PMID 11459964, PMID 11533692, PMID 12205100, PMID 12217790, PMID 12241653, PMID 12460789, PMID 14701743, PMID 15327776, PMID 15367671, PMID 15665856, PMID 1581961, PMID 15829966, PMID 15829967, PMID 15905196, PMID 16239238, PMID 16357170, PMID 16394300, PMID 16912188, PMID 16946210, PMID 17714938, PMID 18024865, PMID 18268546, PMID 18955455, PMID 19049966, PMID 19553641, PMID 19779458, PMID 20551068, PMID 20606085, PMID 20609467, PMID 20609468, PMID 21720365, PMID 21862407, PMID 22203755, PMID 22204724, PMID 22204725, PMID 22237781, PMID 22452356, PMID 22576213, PMID 22711857, PMID 22912389, PMID 23047548, PMID 23118055, PMID 23512992, PMID 23810467

NIH funding

2015 (1), 2016 (1), 2017 (1), 2018 (1), P30CA015083 (1), P50CA247749 (1)